Article Text

Download PDFPDF

  1. Thomas Payne1,
  2. David Jones2,
  3. Khaled El-Ghariani2,
  4. Basil Sharrack3,
  5. Simon Hickman3
  1. 1Northern General Hospital, Sheffield
  2. 2Sheffield Therapeutic Apheresis Unit, NHS Blood and Transplant Service, Royal Hallamshire Hospital
  3. 3Department of Neurology, Royal Hallamshire Hospital


Introduction Plasmapheresis has been shown in a randomised clinical trial (RCT) to be effective in treating corticosteroid-refractory central nervous system (CNS) inflammatory diseases. Data from our centre was compared with the published trial.

Methods A retrospective case note review of patients with CNS inflammatory diseases receiving plasmapheresis was performed. Power and gait scores from Weinshenker et al. (1999) and decimal visual acuity were recorded.

Results Data from 25 patients (optic neuritis=7, multiple sclerosis=12, neuromyelitis optica=4, acute disseminated encephalomyelitis=1, transverse myelitis=1) was reviewed. For the optic neuritis patients the mean visual acuity of the worse affected eye improved from 0.061 to 0.264 (p=0.157), equivalent to a change from approximately 6/100 to 6/24. For patients with a motor deficit, the mean power score improved from 5.78 to 4.78 (p=0.0218) and the mean gait score improved from 7.78 to 6.78 (p=0.0218). The mean motor improvement was from being wheelchair dependent to being able to walk a few steps with bilateral assistance. No benefit was observed if plasmapheresis commenced more than 82.7 days after onset of symptoms. No serious adverse events occurred.

Conclusions Benefits in line with the results of the RCT have been detected supporting the use of plasmapheresis in these diseases.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.